Company profile
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
- CEO
- Mr. Jody Aufrichtig
- Headquarters
- Toronto, ON, Canada
- Employees
- 12
- IPO date
- Jan 25, 2024
- Sector
- Healthcare
- Industry
- Biotechnology